New hypertension drug candidate BCD101 enters first human safety tests
NCT ID NCT07282145
First seen Dec 29, 2025 · Last updated May 14, 2026 · Updated 20 times
Summary
This early-stage study tests the safety and tolerability of a new drug called BCD101 in 56 healthy adults. Participants receive either the drug or a placebo, and researchers monitor for side effects and measure how the drug moves through the body. The goal is not to treat high blood pressure yet, but to gather essential safety data before larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chungbuk National University Hospital
RECRUITINGCheongju-si, North Chungcheong, 28644, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.